Researcher
Patrik Verstreken
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Behavioural neuroscience
- Disciplines (KU Leuven):Neurological and neuromuscular diseases
- See also: Patrik Verstreken (Flanders Institute for Biotechnology)
Affiliations
- Research Group Molecular Neurobiology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - Laboratory of Neuronal Communication (VIB-KU Leuven) (Lab)
Responsible
From1 Jan 2008 → Today - Laboratory of Neuronal Communication (VIB-KU Leuven) (Lab)
Member
From1 Jan 2017 → Today - VIB-KU Leuven Center for Brain & Disease Research (Research Center)
Responsible
From1 Jan 2017 → Today - Verstreken Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Human Genetics (Department)
Member
From1 Apr 2009 → 31 Dec 2016
Projects
1 - 10 of 54
- The Role of Parkinsonism genes in synaptic autophagyFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Tau-dependent synaptic remodeling in health and diseaseFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Translational Markers for Precision Medicine in Modifying Parkinson's DiseaseFrom1 Feb 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Investigating cell type specific defects in protein quality control across the genetic landscape of Parkinson’s diseaseFrom1 Oct 2022 → TodayFunding: FWO junior postdoctoral fellowship
- When size matters: a platform to study molecular interactions and multimerisationFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Dissecting the genetic interactions controlling α-Synuclein accumulation in Parkinson’s DiseaseFrom15 Mar 2022 → TodayFunding: FWO fellowships
- Analyzing the regulation of synaptic vesicle mobility by pre-synaptic liquid phase-separation in health and diseaseFrom7 Mar 2022 → TodayFunding: FWO fellowships
- Therapeutic targeting of pathogenic presynaptic Tau in human neurons in a chimeric Alzheimer’s Disease mouse modelFrom24 Jan 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Investigating cell type specific defects in protein quality control across the genetic landscape of Parkinson’s disease.From1 Oct 2021 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Resilience and vulnerability in the cellular phase of Alzheimer’s disease.From1 Oct 2021 → TodayFunding: BOF - Methusalem
Publications
131 - 140 of 146
- Neurons Generated from APP/APLP1/APLP2 Triple Knockout Embryonic Stem Cells Behave Normally in Vitro and in Vivo: Lack of Evidence for a Cell Autonomous Role of the Amyloid Precursor Protein in Neuronal Differentiation(2010)
Authors: Bruno Bergmans, Ali Shariati, Patrik Verstreken, Carlos Dotti, Bart De Strooper
Pages: 399 - 406 - Neurons Generated from APP/APLP1/APLP2 Triple Knockout Embryonic Stem Cells Behave Normally In Vitro and In Vivo: Lack of Evidence for a Cell Autonomous Role of APP in Neuronal Differentiation(2010)
Authors: Bruno Bergmans, Ali Shariati, Ron Habets, Patrik Verstreken, Luc Schoonjans, Ulrike Müller, Carlos Dotti, Bart De Strooper
Pages: 399 - 406 - Acute inactivation of synaptic proteins(2010)
Authors: Patrik Verstreken
Pages: 393 - 406 - Tweek, an Evolutionarily Conserved Protein, Is Required for Synaptic Vesicle Recycling(2009)
Authors: Patrik Verstreken
Pages: 203 - 215 - Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function(2009)
Authors: Vanessa Morais, Patrik Verstreken, Dominik Haddad, Wim Mandemakers, Bart De Strooper
Pages: 99 - 111 - Conditional Mutagenesis in Drosophila(2009)
Authors: Ching-Man Choi, Sven Vilain, Natalie De Geest, Patrik Verstreken, Bassem Hassan
Pages: 54 - 54 - Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration(2009)
Authors: Ludo Van Den Bosch, Annelies Van Hoecke, Peter Carmeliet, Patrik Verstreken, Wim Robberecht
Pages: 472 - 481 - A novel X-chromosome EMS screen identifies genes implicated in neuronal communication(2009)
Authors: Valerie Uytterhoeven, Jaroslaw Kasprowicz, Sabine Kuenen, Bassem Hassan, Patrik Verstreken
Pages: S45 - S45 - Recombineering-mediated tagging of Drosophila genomic constructs for in vivo localization and acute protein inactivation(2008)
Authors: Jaroslaw Kasprowicz, Bassem Hassan, Patrik Verstreken
- Inactivation of clathrin heavy chain inhibits synaptic recycling but allows bulk membrane uptake(2008)
Authors: Jaroslaw Kasprowicz, Patrik Verstreken
Pages: 1007 - 1016
Patents
1 - 10 of 10
- Screening method for synaptogyrin-3 inhibitors (Inventor)
- Targeting synaptogyrin-3 in tauopathy treatment (Inventor)
- Targeting synaptogyrin-3 in tauopathy treatment (Inventor)
- Means and methods for treatment of early-onset parkinson's disease (Inventor)
- Means and methods for treatment of early-onset parkinson's disease (Inventor)
- Compounds for treatment of intractable epilepsy and doors syndrome (Inventor)
- Targeting synaptogyrin-3 in tauopathy treatment (Inventor)
- Compounds for treatment of intractable epilepsy and doors syndrome (Inventor)
- Restoring phosphorylation of a novel pink1 substrate to treat parkinson's disease (Inventor)
- Restoring phosphorylation of a novel pink1 substrate to treat parkinson's disease (Inventor)